The straight answer
No peptide is a proven treatment for sarcopenia. Nothing here can rebuild the muscle you have lost, and no regulator has approved any peptide for age-related muscle loss. A few compounds touch the right biology, and one or two have even been tested in older adults, but the story is always the same: they can nudge the numbers on a body scan without reliably making you stronger, steadier, or more independent. That last part, real strength and function, is what actually matters, and it is exactly what these drugs have failed to deliver.
What actually treats it
The one thing proven to reverse muscle loss is progressive resistance (strength) training, done regularly and building up over time, paired with enough protein and adequate vitamin D. This is first-line, backed by strong evidence, and it works at any age, including in your 80s and 90s, so it is worth starting even if it feels daunting.
From our library
Compounds here with any tie to muscle loss (sarcopenia) — rated honestly for this specific use.
- Early
ACE-031
SpeculativeThis is the closest the library comes to real human data in aging muscle: a single-dose study in healthy older women showed about 3% more lean mass and 5% more thigh muscle in four weeks by blocking myostatin, the body's 'stop growing muscle' signal. But its maker halted development in 2011 after patients had nosebleeds and skin blood-vessel changes, it was never approved, and animal work hints the extra muscle can actually be weaker and quicker to tire. Promising biology, but a discontinued and unsafe dead end, not a treatment you can or should get.
- Early
Follistatin
SpeculativeFollistatin blocks the same muscle-limiting signals (myostatin and activin) that the more advanced antibody drugs target, so the rationale for muscle wasting is real. The problem is the evidence: it has never been tested as a treatment in a single human trial. Everything about muscle growth comes from mice and cell dishes. The injectable 'Follistatin 344' sold online is an unregulated research chemical with no human safety data.
- Early
SS-31 (elamipretide)
SpeculativeSS-31 protects mitochondria, the cell's energy factories, which run down with age. In a real randomized trial, a single infusion improved the rate of energy (ATP) production in older adults' leg muscle. That is a genuine human signal, and it is now FDA-approved for one rare muscle-weakness disease (Barth syndrome). But better mitochondrial chemistry is not the same as bigger, stronger muscles: it has never been shown to build muscle or reverse sarcopenia, and a larger trial in a related muscle disease missed its main goal.
- Moderate
Tesamorelin
Not reallyIt is a real FDA-approved drug, but for a different job entirely, shrinking deep belly fat in people with HIV, by nudging up your own growth hormone. Growth-hormone boosters like this reliably raise the 'lean mass' number on a scan, but decades of research show that gain is largely fluid and does not translate into real strength or function in older adults. Approved does not mean approved for this.
- Early
Sermorelin
Not reallyAnother growth-hormone-releasing peptide often marketed for 'anti-aging' muscle. The core problem is the same one that sank growth hormone itself as an anti-aging tool: pumping up GH and IGF-1 pads the lean-mass figure without making elderly muscle meaningfully stronger, and it carries real side effects. No trial shows it treats sarcopenia.
- Early
Ipamorelin
Not reallyA cleaner growth-hormone-release peptide, but it falls into the same trap. Its whole appeal is boosting GH, and GH boosting has repeatedly failed to improve strength or physical function in older people, even when the scan numbers move. There is no human trial of ipamorelin for muscle loss.
- Early
MOTS-c
Not reallySold as 'exercise in a shot' because it activates some of the same metabolic switches that training does. That is an appealing idea for someone losing muscle, but all of it is animal and lab work. There are no completed human trials, no established dose, and no evidence it does anything for sarcopenia in people.
Also being studied (not in our library)
- Bimagrumab — The most serious drug in this space. It is an antibody (not one of our peptides) that blocks the same muscle-limiting receptor as ACE-031. In a Phase 2 trial in older adults with sarcopenia it increased muscle mass and improved some strength and mobility, and it is now being studied to preserve muscle during weight-loss drug use. Still investigational, not approved for sarcopenia.
- MK-677 (ibutamoren) — An oral growth-hormone-releasing compound tested in older adults. It raised lean body mass but, tellingly, did not improve muscle strength or function, which is the cautionary tale for this whole GH-boosting category.
- Myostatin/activin antibodies (apitegromab, trevogrumab, taldefgrobep) — A family of injectable antibodies in trials for muscle-wasting conditions. They confirm the myostatin-blocking idea is being taken seriously in real medicine, but none is approved for age-related sarcopenia yet.
Bottom line
There is no peptide you can take today that is proven to treat or reverse sarcopenia; the honest options are drugs that either move a scan number without building real strength, or ones still stuck in animal studies. The real treatment, strength training plus protein, is unglamorous but genuinely works.